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Abstract
Background: General practitioners encounter the vast majority of patients with Epstein-Barr virus-related disease, i.
e. infectious mononucleosis in children and adolescents. With the expanding knowledge regarding the multifaceted
role of Epstein-Barr virus in both benign and malignant disease we chose to focus this review on Epstein-Barr virus-
related conditions with relevance to the general practitioners. A PubMed and Google Scholar literature search was
performed using PubMed’s MeSH terms of relevance to Epstein-Barr virus/infectious mononucleosis in regard to
complications and associated conditions.
Main text: In the present review, these included three early complications; hepatitis, splenic rupture and airway
compromise, as well as possible late conditions; lymphoproliferative cancers, multiple sclerosis, rheumatoid arthritis, and
chronic active Epstein-Barr virus infection. This review thus highlights recent advances in the understanding of Epstein-Barr
virus pathogenesis, focusing on management, acute complications, referral indications and potentially associated
conditions.
Conclusions: Hepatitis is a common and self-limiting early complication to infectious mononucleosis and should be
monitored with liver tests in more symptomatic cases. Splenic rupture is rare. Most cases are seen within 3 weeks after
diagnosis of infectious mononucleosis and may occur spontaneously. There is no consensus on the safe return to
physical activities, and ultrasonic assessment of spleen size may provide the best estimate of risk. Airway compromise
due to tonsil enlargement is encountered in a minority of patients and should be treated with systemic corticosteroids
during hospitalization. Association between lymphoproliferative cancers, especially Hodgkin lymphoma and Burkitt
lymphoma, and infectious mononucleosis are well-established. Epstein-Barr virus infection/infectious mononucleosis as
a risk factor for multiple sclerosis has been documented and may be linked to genetic susceptibility. Chronic active
Epstein-Barr virus infection is rare. However, a general practitioner should be aware of this as a differential diagnosis in
patients with persisting symptoms of infectious mononucleosis for more than 3 months.
Keywords: Epstein-Barr virus. Infectious mononucleosis, Hepatitis, Splenic rupture, Airway compromise,
Lymphoproliferative cancer, Multiple sclerosis, Rheumatoid arthritis, General practice, Family practice
Background
Epstein-Barr virus (EBV) is a double-stranded DNA virus
belonging to the Herpes family and the primary cause of
infectious mononucleosis (IM), a common infection
worldwide with a lifetime prevalence of 90% [1].
Symptoms of IM, so-called glandular fever usually mani-
fest after an incubation period of four to seven weeks, and
include fever, lymphadenopathy and pharyngitis. The vast
majority of IM cases are self-limiting with an excellent
prognosis, but in rare cases acute complications such as
splenic rupture, hepatitis and severe tonsil enlargement
with airway obstruction are encountered [2].
EBV has also for long been known to be an implicate
in other conditions than IM. A simple literature search
produces an extensive list of associations derived from
case-reports through large epidemiologic studies such as
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lymphoproliferative disorders, head and neck cancer,
breast cancer, systemic lupus erythematosus, vitamin D
deficiency, chronic fatigue syndrome, thyroid disorders,
rheumatoid arthritis (RA), multiple sclerosis (MS) as
well as other autoimmune disorders. Concerning malig-
nant disease alone, it has been estimated that EBV is as-
sociated with close to 200,000 malignancies worldwide
each year, which has led to increasing interest in a vac-
cine against EBV infection [3, 4].
General practitioners (GPs) encounter the vast majority
of patients with EBV-related disease, i.e. glandular fever in
children and adolescents. They diagnose millions of cases
yearly, give advice concerning management including re-
striction of physical activity and alcohol consumption and
in some cases, refer patients to secondary care due to
complications of the infection. Furthermore, GPs are
prompted by their patients regarding risk of potentially as-
sociated conditions when infected with EBV. Therefore,
GPs need to be able to recognize signs of IM, the possible
differential diagnoses, evaluate the risks of complications
and provide evidence-based recommendations for the in-
dividual patient.
With the expanding knowledge regarding the multifa-
ceted role of EBV in both benign and malignant disease
we chose to focus this review on EBV-related conditions
of relevance to the GP. This review will discuss IM and
three acute complications to IM; hepatitis, splenic rupture
and airway compromise. Furthermore, we will address late
associations to EBV/IM which the GP may be consulted
about; lymphoproliferative cancers, MS, RA and chronic
active Epstein-Barr virus infection (CAEBV).
Material and methods
A PubMed and Google Scholar literature search was
performed. We used PubMed’s MeSH terms IM,
Epstein-Barr virus, human herpesvirus 4, HHV-4, mono-
nucleosis, glandular fever, lymphoma, lymphoprolifera-
tive disorder/cancer, lymph node cancer, multiple
sclerosis, MS, disseminated sclerosis, rheumatoid arth-
ritis, RA, hepatitis, hepatic function, liver insufficiency,
liver failure, respiratory insufficiency/failure/distress,
hypoxia, airway compromise/obstruction and splenic
rupture. We then screened abstracts to assess whether
the search results were of relevance for the focus of this
review. Systematic reviews, meta-analyses and Cochrane
reviews were prioritized. Case-reports were included as
citations for uncommon outcomes and outliers to the
general consensus. Articles focusing on EBV-associated
IM were given priority over other IM-causing pathogens.
Same priority was given to articles focusing on immuno-
competent individuals and young adults/adults over chil-
dren. As the number of relevant articles increased so did
the number of relevant references and keywords which
refined our literature search on PubMed, and numerous
relevant articles were presented through the ‘Similar ar-
ticles’ tab on PubMed. This approach produced a pool
of 96 relevant research articles including one umbrella
review, six systematic reviews (including one Cochrane
review), three meta-analyses, 36 reviews and 11 case re-
ports, with publishing span from 1992 to 2019. Contra-
dicting results and alternative perspectives on the
subject were noted and presented.
Main text
Infectious mononucleosis
Pathogenesis
90% of IM cases are caused by EBV with the remaining
10 % caused by cytomegalovirus (CMV), human herpes-
virus 6, herpes simplex virus type 1 and human im-
munodeficiency virus (HIV) [5]. EBV is found in saliva
and is therefore transmitted through coughing, the shar-
ing of food, kissing (hence the layman’s term ‘kissing de-
cease’), etc. Low amounts of EBV may be detected in
saliva throughout life in infected individuals. Peak levels
are seen during the acute phase if the infection [6], how-
ever, a study has shown that patients may be highly con-
tagious up to 180 days after the onset of symptoms and
maybe even past that [7]. After successful transmission,
EBV infects epithelial cells and resting B-cells in the oro-
pharynx, starts replicating and thereby spreads through-
out the body. This process represents the incubation
period, which lasts about six (four to seven) weeks [8]
and leads to an activation of cytotoxic T-lymphocytes
(CTL) and natural killer cells. The activation of CTL in
primary infection leads to cell-mediated immune re-
sponse causing the clinical presentation of IM. However,
when EBV infects B cells, the virus is able to restrict its
expression of genes to nine proteins (out of approxi-
mately 100) thereby avoiding recognition of CTLs, and
thus resulting in latent infection in the affected B-cells.
Different patterns of these expressed so-called latency
proteins have been described and seem to associate to
different EBV-associated lymphoproliferative conditions
such as Hodgkin Lymphoma (HL), Burkitt Lymph-
oma (BL) and post-transplant lymphoproliferative dis-
order (PTLD) depending on the expression pattern,
please refer below. Reactivation of EBV may also occur
in later life in the immunocompromised as seen after
transplants, due to immunosuppressive medication, ac-
quired immune deficiency syndrome (AIDS), etc. [9].
Clinical presentation
Whether an individual develops IM primarily depends
on the timing of exposure to the virus. Young children
rarely develop clinical signs of IM, whereas up to 70%
[10] of adolescents and adults will present with the clas-
sical symptomatic triad of about two to four weeks of
fever, pharyngitis and cervical lymphadenopathy with
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lymphocytosis [1]. The risk of severe symptoms is posi-
tively correlated to the age of the patient at time of pri-
mary infection [11]. This is of importance since
debuting patient age has increased in the last past 15
years, thereby rendering more individuals at risk of se-
vere IM [11]. White tonsillar exudates, sometimes even
covering the tongue may be seen and distinguish IM
from the more spotted coverings seen in bacterial tonsil-
litis [6]. Palatal petechiae have been reported in up to
50% of cases [6]. Hepatosplenomegaly and some degree
of hepatitis are also common findings. In approximately
75% of cases there is a subclinical increase in alanine
aminotransferase (ALAT) and about five to 10 % may
present with jaundice due to diffuse damage to the liver
parenchyma [8]. Splenomegaly may not be noticeable
upon physical examination, but ultrasonic assessment of
splenic size during acute IM has shown that all patients
develop splenomegaly in varying degrees [12]. Patients
with IM are therefore routinely advised to limit physical
activity for at least 1 month after the onset of symptoms,
however, there is yet to be developed a method of pre-
dicting the risk of splenic rupture [13]. Thus the “classic”
patient with uncomplicated IM may be summarized with
the following presentation; fever, pharyngitis, cervical
lymphadenopathy, lymphocytosis, palatal petechiae and
hepatosplenomegaly and with elevated ALAT.
Diagnosis
Though patients with IM often present with the afore-
mentioned triad of symptoms, a GP should always con-
sider the array of illnesses that can cause IM-like
symptoms. A thorough history of the patient should elu-
cidate recent travel- and sexual history, contact with ani-
mals, previous medical problems and family history of
disease. An excellent review from 2007 concerning the
diagnostic process for IM-like disease, has summarized
conditions that may mimic IM, and that should be con-
sidered depending on the medical and personal history
of the patient [5]. An algorithmic approach to the pa-
tient at this point is recommendable. Pregnancy, intra-
venous drug use or men having sex with men should
prompt the GP to be even more alert. In pregnancy,
serological testing for CMV and toxoplasmosis should
be undertaken in addition to EBV. The latter two groups
should be tested for HIV as well [6].
If a patient does not classify as high risk, as defined
above, the next step is blood testing (heterophile anti-
body test (Monospot test)) as well as a complete blood
count (CBC). About 85% of patients with EBV-related
IM, will have a positive heterophile antibody test, but
the amount of heterophile antibodies may not be above
the limit of detection within the first week of symptoms.
This phenomenon can result in a false-negative rate of
25% in this period. However, a heterophile antibody test,
with a sensitivity of 63–84% and a specificity of 84–
100% [14], is still considered the best initial diagnostic
test for EBV-related IM, due to its low cost and fast
turn-around time. If a patient is truly heterophile
antibody-negative, the GP should bear in mind that
some 10 % of patients with IM are consistently
heterophile-negative. In these cases, the EBV viral capsid
antigen (VCA) IgG and IgM antibody test is of diagnos-
tic value in the acute phase [5]. Additional testing for
EBV nuclear antigen (EBNA) antibodies may help to dis-
tinguish between acute and past infection [15]. VCA and
EBNA antibody tests offer higher sensitivity and specifi-
city, but come at a higher price and take longer to
analyze. In case of a heterophile antibody- and
VCA-IgM-negative patient, a CBC may be used for fur-
ther diagnostic workup. A diagnostic algorithm for use
in primary care has been summarized in a recently pub-
lished clinical review (Fig. 1) [6].
Treatment
There is currently no specific treatment for IM. Manage-
ment focuses on symptomatic relief and patients are
therefore treated with simple analgesics, antipyretics, hy-
dration and rest. Of interest, a systematic review from
2002 advises against prolonged rest due to possible
deconditioning. Deconditioning may cause prolonging of
symptoms including fatigue and increases recovery time
and patients should be allowed out of bed as soon as
they feel fit enough [16]. There has been controversy
surrounding a possible link between acute viral infec-
tions, such as IM, and chronic fatigue syndrome (CFS),
but at present, it is unlikely that an acute EBV infection
leading to IM can cause CFS by itself [6]. Antivirals for
IM has been proposed for some time. However, there
has not been any firm evidence to support this notion. A
Cochrane review from 2016 concluded that the effective-
ness of antiviral agents (acyclovir, valomaciclovir and
valacyclovir) in acute IM is uncertain and that the qual-
ity of the evidence was low [17]. Thus, at the moment
treatment should focus on supportive care which in se-
vere cases may require hospitalization for intravenous
fluids due to dehydration or monitoring for impeding re-
spiratory failure.
Early complications to infectious mononucleosis
Hepatitis
As mentioned, parenchymal injury of the liver tissue is
common with about 75% of patients exhibiting a two to
three fold increase in ALAT during the acute phase of
infection [8] with levels returning to normal after about
three weeks [18]. Cholestatic liver disease and chronic
hepatitis due to EBV are rare complications, but have
been described in the literature [19–21]. The hepatic
changes are therefore usually transient and self-limiting,
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but cases of liver failure with fatal outcomes - even in
immunocompetent patients - have been reported [22,
23] which is why it is advisable to order liver tests upon
diagnosis and during monitoring of patients with more
severe IM.
Splenic rupture
Splenic rupture, as a result of splenomegaly and altered
splenic architecture [24], is probably the most feared
and acute complication to IM. It is, however, a very rare
complication with an incidence varying from 0.1–0.2%
[25] to 0.5% [26], and with most cases occurring within
the first 3 weeks after diagnosis. This is supported by a
study of the ultrasonic assessment of splenic size during
IM in athletes, which showed a peak increase 12.3 days
after onset of symptoms. The study also demonstrated a
predictable rate of regression of spleen size of about 1 %
per day after the peak size [12]. The risk of splenic rup-
ture is anecdotally highest in patients who are involved
in contact sports like martial arts, football, hockey, etc.,
and activities with high intraabdominal pressure like
weightlifting. Athletes are withheld from practice and
competition during this phase of the infection, which
may have implications for their academic- and athletic
career, especially in countries like the US where athletic
scholarships can determine whether a student goes to
college. Much literature has therefore focused on the
safe return to sports. There seems to be a current con-
sensus that return to non-contact activities can com-
mence 3 weeks after symptomatic onset [25]. On the
other hand, recommendations regarding the return to
contact sports vary, ranging from three to 5 weeks to 6
months [27]. Multiple attempts have been made to make
clinical guidelines, but none have been accepted as gen-
eral practice. One of the more sophisticated attempts
was made by McKeag et al who focused on time from
onset of symptoms and criteria such as fever, lymph-
adenopathy, bilirubin- and liver enzyme levels and ab-
sence of splenomegaly verified radiographically [27].
Still, several cases of spontaneous splenic rupture have
been reported [28] and splenic rupture should therefore
be suspected in all patients presenting with acute ab-
dominal- or chest pain and with confirmed- or sus-
pected IM.
Airway compromise
Cervical lymphadenopathy is a hallmark in IM and in-
volves the nasopharyngeal and palatal tonsils. Swelling
has been estimated to cause airway compromise in 1–
3.5% of IM cases [2] – and more common among youn-
ger children [29]. Symptoms include stridor, cyanosis
and tachypnea and should lead to immediate admittance
Fig. 1 Algorithm for diagnosing IM. Adapted with permission from Lennon et al. [6]
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and treatment. Systemic corticosteroids are used in pa-
tients with risk of airway compromise and show signifi-
cant results within 12–36 h if treated aggressively. Early
treatment with systemic corticosteroids may therefore
limit the need for surgical intervention in severe cases
[29]. Tracheotomy has only been used in extremely se-
vere (and exceptionally described) cases, where treat-
ment with systemic corticosteroids have failed [29].
Selected use of acute tonsillectomy in patients who have
not responded satisfactorily to systemic corticosteroids
has been proposed by some groups [30, 31], but has
been a topic of debate, due to the conflicting data on the
risk of bleeding. A study from 2005 reported that 27 of
205 (13%) patients experienced post-operative bleeding,
with a total of 36 cases with a bleeding episode (18%).
These results were not supported by those advocating
for selected use of acute tonsillectomy [30, 31] and it
seems that more research on this topic is warranted. Of
importance, treatment with systemic corticosteroids is
only warranted in an emergency setting, in the case of
acute complications such as impending airway com-
promise. Systemic corticosteroids should not be insti-
tuted for symptomatic relief as it does not affect the
incidence of complications nor rates of admission or
length of hospitalization [32].
Late complications to EBV/IM
Lymphoproliferative cancers
Lymphoproliferative cancers are the most
well-established late-onset complication to IM and have
been investigated in several different cohorts since the
1970s. A Scandinavian study from 2003 found an in-
creased risk of EBV-positive HL in young adults, with an
odds ratio (OR) of 2.7 (95% confidence interval (CI): 1.2
to 6.0), and a median incubation period of 4.1 years with
a peak risk after 2.1 years after primary infection [3]. A
British study from 2009 found similar results in two dif-
ferent cohorts. Both showed elevated risk of HL with
rate ratios of 3.2 (95% CI: 1.2–7.0) and 6.0 (95% CI: 2.4–
12.5), respectively [33]. An Italian multicenter
case-control study from 2000 also observed an increased
risk, with an age-adjusted OR of 4.4 (95% CI: 1.1–16.6).
This study also demonstrated an increased risk of
non-Hodgkin lymphoma (NHL), with an age adjusted
OR of 4.0 (95% CI: 1.4–11.8) [34]; results that could not
be confirmed by the Scandinavian study, however. Over-
all, published data seem to agree on a strong correlation
between IM and HL where results concerning NHL in
general are more conflicting. On the other hand, for cer-
tain NHL subtypes a strong correlation seems to exist.
The carcinogenic properties of EBV was first hypothe-
sized in 1964, when EBV was observed in cultured
tumor cells from patients with BL in tropical Africa.
This highly aggressive type of B-cell lymphoma has since
been strongly correlated to EBV. There are three sub-
types of BL; endemic, sporadic and immunodeficien-
cy-associated, where the endemic subtype has shown the
strongest correlation with EBV [35]. EBV status does not
affect the treatment regime however, which consists of
high-intensity chemotherapy and anti-CD20 monoclonal
antibody therapy in fit patients and results in remission
in > 85% of cases [36]. EBV has also been associated with
diffuse large B-cell lymphoma (DLBCL) in 10 % of cases
among immunocompetent patients. EBV-positive
DLBCL seems to affect primarily elderly patients and is
now termed EBV(+) DLBCL, not otherwise specified
(NOS). This condition has shown to impair prognosis as
these patients tend to respond poorly to conventional
therapy [36].
As previously discussed, IM may lead to airway com-
promise as the mentioned lymphoproliferative cancers
may themselves cause airway obstruction. However, this is
not within the scope of this review nor relevant to a GP.
Multiple sclerosis
There is a substantial controversy concerning the causa-
tive role of EBV in the development of MS. It seems
clear, however, that there is an association. A
meta-analysis from 2006 showed that the risk of MS in
EBV-negative individuals was close to zero whereas the
incidence rate rose in EBV-positive individuals without
clinical IM. Furthermore, the risk of MS was 2.3 times
higher in individuals with a late EBV infection and his-
tory of IM than in EBV-positive individuals without a
history of IM. The study also found that the incidence
rate peaked around the age of 25–30 and declined to al-
most zero around 60 years of age [37]. A large umbrella
review published in 2015, studying 44 different proposed
risk factors for MS found similar results, with strong
epidemiological evidence for IM as a risk factor for MS
[38]. A study of the correlation of IM and initial symp-
toms of MS from 2017 supports a causative relationship
between IM and MS and state that the rate of which MS
develops could depend on genetically susceptibility to
EBV infection as well as time of infection, with postpu-
bescent infection being critical for the initiation and
rapid development of MS [39]. Despite the published
data, it is a challenge to prove underlying mechanisms.
Humanized mouse models have been studied, but
graft-versus-host reactions have been major confounders
in these studies [40]. A study from 2013 on this contro-
versy summarized the key issues in the debate: There is
currently no consensus as to whether patients with MS
has EBV-infected B-cells in the CNS [41]. This is further
complicated by the “Hit-and-Run” hypothesis, which de-
scribes how EBV is able to ‘escape’ EBV-induced malig-
nant cells after infection with no trace of virus itself
[42]. However, it is not clear if this hypothesis only
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applies to malignant cells, or if EBV has a general ability
to make a clean ‘escape’ from all types of infected cells
including B-cells, which serve as essential implicants in
MS [43]. If there indeed exits a causal link between EBV
and MS, this would support that vaccination against
EBV could have the potential to eliminate MS as one
study suggests or, that insuring early life exposure to
EBV could decrease the risk of developing MS, as indi-
viduals with a history of symptomatic IM exhibit a 2.3
times higher risk than EBV-positive individuals without
a history of IM as mentioned above [37]. There is yet to
be marketed such a vaccine, although a phase 2
placebo-controlled randomized clinical trial reported a
reduced incidence of IM by 78%, however, the vaccine
did not protect against EBV infection [44].
Rheumatoid arthritis
A causal link between RA and IM has been proposed
alongside several other autoimmune diseases. However,
a large systematic review and meta-analysis from 2015
found no significant association. The authors concluded,
however, that several of the included studies had limita-
tions and that more data on the subject was needed [45].
At present, no data demonstrate a clear association be-
tween EBV and RA, but it is worth acknowledging the
increasing amount of literature suggesting diverse roles
of EBV in autoimmune disease.
Chronic active Epstein-Barr virus infection
CAEBV is rare and mostly limited to Japan and East
Asia, but has gained international attention due to an in-
crease in cases worldwide. Although rare, a GP should
be aware of this as a differential diagnosis in patients
with IM-symptoms persisting for more than 3 months,
after exclusion of IM, autoimmune disease and immuno-
deficiency disorders (congenital or acquired) [46]. Fur-
ther diagnostic work should be performed by a specialist
in haematology.
Conclusions
The expanding roles of EBV in both benign and malig-
nant disease bear witness of a viral species with diverse
effects on the human body. GPs encounter the vast ma-
jority of patients exhibiting symptoms indicative of the
most common EBV infection, IM. GPs of today there-
fore need to be aware of not only the classical early
complications to IM, but also late complications and po-
tential associated conditions as patients are entitled to
evidence-based risk estimates of such outcomes.
Upon initial evaluation of a patient with symptoms
suggestive of IM an algorithmic approach is recom-
mended to ensure correct diagnosis and proper risk
stratification. Treatment should focus on symptomatic
relief and rest; however, prolonged bed-rest is
discouraged as deconditioning may prolong symptoms
and recovery time. Hospitalization can be necessary in
severe cases of dehydration and impeding respiratory
failure. Hepatitis is a common and self-limiting early
complication to IM, but liver tests should be monitored
in more symptomatic cases as fatal events have been re-
ported. Also, splenomegaly may be noticed upon phys-
ical examination and consequently increases the risk of
splenic rupture. Splenic rupture is rare, however, and
most cases are seen within 3 weeks after diagnosis of IM
and may occur spontaneously. Currently, there is no
consensus on the safe return to physical activities, and
ultrasonic assessment of spleen size may provide the
best estimate of risk. Airway compromise due to tonsil
enlargement is encountered in a minority of patients (1–
3.5%) and is more common among younger children. Such
patients should be admitted to pediatric wards, where early
intervention with systemic corticosteroids limits the need
for surgical intervention and thereby the risk of
post-operative bleeding, infection and prolonged
hospitalization.
The level of evidence for the late complications varies,
but the association between lymphoproliferative cancers,
especially HL and BL, and IM are well-established.
Epstein-Barr virus infection/IM as a risk factor for MS
has been documented and may be linked to genetic sus-
ceptibility, however the pathological mechanisms are yet
to be described. Regarding RA and EBV, there is no sig-
nificant association. CAEBV is rare, but a GP should be
aware of this as a differential diagnosis in patients with
persisting IM-symptoms for more than 3 months.
Due to the high prevalence of EBV-infected individuals
throughout the world, and the known and proposed late
complications to IM, preventive measures should be pri-
oritized, ideally through vaccination. Current vaccination
studies have shown success as far as preventing IM in
78% of cases, but does not prevent the infection with
EBV. Future research will hopefully shed light on costs,
benefits, side-effects and target-groups as well as de-
termining whether the prevention of EBV-infection in
general - or the prevention of IM in particular - is
the primary goal. Furthermore, future research should
focus on substantiating the known- and proposed as-
sociations and causations in order to contribute to
the understanding of the pathogenic mechanisms of
EBV.
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